Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia
NCT ID: NCT00358046
Last Updated: 2007-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
120 participants
INTERVENTIONAL
2006-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose-finding Study of KHK7791 in Hyperphosphatemia Patients
NCT03864458
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 At Fixed Doses in Patients with Hyperphosphatemia
NCT06712654
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
NCT00506441
Dose Finding Study to Treat High Phosphate Levels in the Blood.
NCT02081534
A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
NCT02965053
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ILY101
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prior successful use of phosphate binder
* Signed informed consent
Exclusion Criteria
* Kidney transplant planned within 3 months
* Pregnant or lactating women, or women of child bearing potential not using an acceptable form of birth control
* Clinically significant liver disease
* History of bowel obstruction or other significant gastrointestinal disorder
Additional study entry criteria will be evaluated during initial screening.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ilypsa
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guido Smeets, MD
Role: STUDY_DIRECTOR
Ilypsa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Study Site
Mobile, Alabama, United States
Clinical Study Site
Mountain View, California, United States
Clinical Study Site
Riverside, California, United States
Clinical Study Site
San Diego, California, United States
Clinical Study Site
Thornton, Colorado, United States
Clinical Study Site
Ocala, Florida, United States
Clinical Study Site
Palm Beach Gardens, Florida, United States
Clinical Study Site
Pembroke Pines, Florida, United States
Clinical Study Site
Des Moines, Iowa, United States
Clinical Study Site
Baton Rouge, Louisiana, United States
Clinical Study Site
Rochester, New York, United States
Clinical Study Site
Allentown, Pennsylvania, United States
Clinical Study Site
Houston, Texas, United States
Clinical Study Site
San Antonio, Texas, United States
Clinical Study Site
Provo, Utah, United States
Clinical Study Site
Salt Lake City, Utah, United States
Clinical Study Site
Norfolk, Virginia, United States
Clinical Study Site
Appleton, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ILY-1201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.